Cannabinoid Encyclopedia

Focused research review

What does research say about CBG and skin health?

CBG has early topical and skin-biology research, including limited human work. That is not enough to say it treats a skin condition.

Updated July 2026 14 research sources Human and early research

The short answer

What is the bottom line?

CBG skin research is promising enough to study further, not to claim treatment. 1 2 3

The current source set includes topical, cell, microbial, and limited human skin research. Those studies use different products and outcomes, so they do not establish a general CBG result for acne, dermatitis, inflammation, or other skin conditions. 1 2 3

What this means: Topical CBG research should be read product by product and outcome by outcome. A skin-biology signal or small human study cannot substitute for robust clinical evidence for a specific condition. 1 2 3

How to read this answer: Topical CBG research should be read product by product and outcome by outcome. A skin-biology signal or small human study cannot substitute for robust clinical evidence for a specific condition. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBG and skin health.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    CBG skin evidence includes topical and laboratory studies, with limited human research. 1

  2. 2

    Different skin products, models, and outcomes cannot be combined into one general result. 2

  3. 3

    Early topical research does not establish that CBG treats a skin disease or replaces clinical care. 3

Choose your question

What do you want to know about CBG and skin?

Start with the level of evidence: laboratory biology, topical product testing, or a human outcome.

  1. 01Reader question

    What human skin research exists?

    See the limited human and topical sources in the current set.

    Explore the evidence
  2. 02Reader question

    What do laboratory studies show?

    Explore the cellular and microbial context without treating it as a clinical result.

    Explore the evidence
  3. 03Reader question

    Does a topical formula change the answer?

    Yes. The formulation is part of what each source tested.

    Explore the evidence

Research areas

What researchers studied about CBG and skin health

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

Skin and inflammatory dermatology

This part of the literature focuses on Skin and inflammatory dermatology. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

5 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

Not prominent

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

7 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 2 of 14 research sources could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBG and skin health is not one kind of study. This source set includes 7 cell or laboratory studies, 3 animal studies, and 1 clinical study in people. 3

The recorded populations or models include people or patients (5 sources), cells or tissue models (4 sources), and animal models (3 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is skin, dermatology, or topical inflammatory outcomes (14 sources). Closely related outcome names can still describe different measurements. 5

The CBG and skin health source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

clinical study in people

In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties.

On this page, this source examines CBG and skin and inflammatory dermatology. 1

Study type
clinical study in people
Population or model
people or patients
Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

evidence still limited

Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota.

On this page, this source examines CBG and skin and inflammatory dermatology. 2

Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
evidence still limited

animal study

Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway.

On this page, this source examines CBG and skin and inflammatory dermatology. 3

Study type
animal study
Population or model
animal models
Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

cell or laboratory study

A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells.

On this page, this source examines CBG and skin and inflammatory dermatology. 4

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

cell or laboratory study

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential.

On this page, this source examines CBG and skin and inflammatory dermatology. 5

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
skin, dermatology, or topical inflammatory outcomes
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

Research on CBG and skin health should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

Does CBG help skin?

The current evidence includes early topical and skin-biology research, but it does not establish that CBG treats a skin condition. 7

Are laboratory skin studies the same as clinical studies?

No. Cell and microbial studies can reveal biological activity, while clinical studies test outcomes in people using a defined product. 8

Why does the product matter for topical CBG?

A topical product can differ in concentration, other ingredients, vehicle, application method, and testing conditions. Those details can change the result. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. clinical study in people; mechanism-focused research PubMed 35056807 DOI 10.3390/molecules27020491
  2. 2
    Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. evidence still limited PubMed 36768709 DOI 10.3390/ijms24032389
  3. 3
    Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. animal study; mechanism-focused research PubMed 39851511 DOI 10.3390/cells14020083
  4. 4
    A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. cell or laboratory study; mechanism-focused research PubMed 39357769 DOI 10.1016/j.ejps.2024.106920
  5. 5
    Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research PubMed 39596290 DOI 10.3390/ijms252212224
  6. 6
    The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research PubMed 36916438 DOI 10.1016/j.biopha.2022.114163
  7. 7
    Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. human research PubMed 40124934 DOI 10.2147/ccid.s472746
  8. 8
    Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. animal study; mechanism-focused research PubMed 40725084 DOI 10.3390/ijms26146840
  9. 9
    Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. cell or laboratory study; evidence still limited PubMed 41645347 DOI 10.1186/s42238-026-00403-1
  10. 10
    Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research PubMed 27094344 DOI 10.1111/exd.13042
  11. 11
    Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. cell or laboratory study; mechanism-focused research PubMed 37949940 DOI 10.1038/s41598-023-45565-7
  12. 12
    Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. evidence still limited PubMed 38889235 DOI 10.1021/acs.jnatprod.4c00212
See all 14 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39596290
  2. The antinociceptive activity and mechanism of action of cannabigerol. animal study; preclinical research / 1 linked research note PubMed 36916438
  3. Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. animal study; mechanism-focused research / 1 linked research note PubMed 40725084
  4. Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. evidence still limited / 1 linked research note PubMed 36768709
  5. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. clinical study in people; mechanism-focused research / 1 linked research note PubMed 35056807
  6. Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. animal study; mechanism-focused research / 1 linked research note PubMed 39851511
  7. Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. human research / 1 linked research note PubMed 40124934
  8. Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37949940
  9. Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39647320
  10. Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. evidence still limited / 1 linked research note PubMed 38889235
  11. The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37652708
  12. A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39357769
  13. Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. cell or laboratory study; evidence still limited / 1 linked research note PubMed 41645347
  14. Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 27094344